NCT05614349 (CanTreatCOVID) is a Phase 3 clinical trial of Paxlovid in COVID-19, sponsored by Unity Health Toronto.

Who is sponsoring NCT05614349?

NCT05614349 is sponsored by Unity Health Toronto.

What drugs are being tested in NCT05614349?

Interventions in NCT05614349: Paxlovid, Antioxidant.

Is NCT05614349 still recruiting?

NCT05614349 is currently active, enrolled. Last updated 16 May 2025.

Last reviewed 2025-05-16 · How we verify

NCT05614349: CanTreatCOVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

Active, enrolled Phase 3 Last updated 16 May 2025

What this trial tests

Phase 3 trial testing Paxlovid in COVID-19 in 797 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 January 2023

Primary endpoint
28 April 2025

28 June 2025

Quick facts

Lead sponsor	Unity Health Toronto
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	797
Start date	16 January 2023
Primary completion	28 April 2025
Estimated completion	28 June 2025
Sites	6 locations across Canada

Drugs / interventions tested

Paxlovid (paxlovid) — full drug profile →
Antioxidant — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Unity Health Toronto — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CanTreatCOVID is an open-label, individually randomized, multi-centre, national trial. CanTreatCOVID aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for SARS-CoV-2 for non-hospitalized patients in Canada. Participants will be randomized to receive usual care (i.e. supportive care and symptom relief) or a study therapeutic, which will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee. The primary outcomes being evaluated is hospitalization and/or death at 28 days, as well as time to recovery.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S, Metzendorf MI, Kuehn R, Popp M, et al · · 2023 · cited 16× · PMID 38032024 · DOI 10.1002/14651858.cd015395.pub3
Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings.
Hosseini B, Condon A, da Costa BR, Daley P, et al · · 2025 · cited 1× · PMID 40754325 · DOI 10.1136/bmjopen-2024-097134
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
Butler CC, Pinto AD, Harris V, Holmes J, et al · · 2026 · PMID 42019019 · DOI 10.1056/nejmoa2502457
Lessons learned and recommendations from the Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID).
Hosseini B, Condon A, da Costa BR, Daley P, et al · · 2026 · PMID 41985658 · DOI 10.1016/j.cct.2026.108303
Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID): recruitment strategies of a decentralized, national randomized controlled trial for acute SARS-CoV-2.
Astorga GH, Pinto AD, Sivayoganathan K, Maruthananth K, et al · · 2026 · PMID 41756075 · DOI 10.3389/fpubh.2026.1698604
Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomized controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings
Hosseini B, Condon A, da Costa BR, Daley P, et al · · 2024 · DOI 10.1101/2024.11.25.24317904

Verify or expand the search:

Other trials of Paxlovid

Trials testing the same drug.

NCT06397144 — A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Heal · Phase 1 · withdrawn
NCT06349655 — The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19 · completed
NCT05965726 — RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms · Phase 2 · completed
NCT05792865 — A Registry Study of Patients Hospitalized With Confirmed COVID-19 · unknown
NCT05341609 — Efficacy and Safety of JT001 (VV116) Compared With Paxlovid · Phase 3 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Unity Health Toronto trials

Trials by the same sponsor.

NCT07507409 — Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients · Phase 4 · not yet recruiting
NCT07455487 — First Appendectomy Using Revolve Surgical Robotic Arm · NA · not yet recruiting
NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
NCT07314905 — Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) · Phase 3 · not yet recruiting
NCT06571916 — Brief Skills for Safer Living (Brief-SfSL) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05614349 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Unity Health Toronto
Last refreshed: 16 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05614349.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing